Accounts receivable, net of allowance for credit losses of 5,296 and 3,192 at 2025 and 2024, respectively
110,258
113,909
Inventories
58,241
59,773
Prepaid expenses
10,056
10,516
Income taxes receivable
14,716
14,043
Other current assets
8,014
8,248
Total current assets
226,914
237,677
Property, plant and equipment, net of accumulated depreciation of 321,113 and 314,317 at 2025 and 2024, respectively
98,031
97,927
Right of use assets
53,980
55,116
Intangibles, net of accumulated amortization and impairment of 19,470 and 19,326 at 2025 and 2024, respectively
6,107
6,170
Goodwill
100,012
99,996
Deferred tax assets, net
70,506
70,479
Other assets
35,810
34,746
Total assets
591,360
602,111
Accounts payable
36,945
41,699
Accrued payroll and related costs
23,363
25,319
Taxes other than payroll and income
3,852
3,623
Unearned revenues
7,258
9,115
Operating lease liabilities
11,474
11,508
Income taxes payable
3,513
4,385
Other current liabilities
9,338
9,123
Total current liabilities
95,743
104,772
Total long-term debt
117,000
-
Less debt issuance costs
2,897
-
Long-term debt, net
114,103
124,613
Long-term operating lease liabilities
41,525
42,420
Deferred compensation
31,054
29,639
Deferred tax liabilities, net
10,102
11,482
Other long-term liabilities
21,445
21,882
Common stock, 200,000,000 shares authorized, 0.01 par value, 46,966,868 issued and 46,086,944 outstanding at 2025 46,966,868 issued and 46,826,820 outstanding at 2024
470
470
Additional paid-in capital
113,874
112,763
Retained earnings
173,598
159,824
Accumulated other comprehensive income (loss)
-5,984
-5,957
Treasury stock (at cost), 879,924 and 140,048 shares at 2025 and 2024, respectively
10,611
5,817
Total core laboratories inc. shareholders' equity
271,347
261,283
Non-controlling interest
6,041
6,020
Total equity
277,388
267,303
Total liabilities and equity
591,360
602,111
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.